Form 4: Revolution Medicines Executive Sells Shares to Cover Tax Obligations

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 3,349 shares of common stock on June 17, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 3,349 shares of common stock on June 17, 2024.
• The sale was executed at a weighted average price of $37.387 per share, with individual trades ranging from $37.3867 to $37.3887.
• The transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023, to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs).
• Following the transaction, Kelsey beneficially owns 269,073 shares, including 95,476 RSUs and 1,513 shares acquired under the Employee Stock Purchase Plan on May 31, 2024.

Sentiment

Score: 5

Explanation: The document reports a routine stock sale by an executive to cover tax obligations, which is neither particularly positive nor negative.

Industry Context

Sales by company executives are a normal part of corporate governance. Often these sales are planned in advance to avoid any perception of insider trading. It is common for executives to sell shares to cover tax obligations related to vesting equity.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the context of tax obligations and the pre-arranged trading plan.

Key Dates